Sorry, you need to enable JavaScript to visit this website.

Anti-Infectives Areas of Interest

  • Ceftazidime-avibactam

    Research areas to be considered for support:

    • Microbiology and surveillance studies, invitro synergy studies with other antibiotics
    • Clinical efficacy 
    • Tissue penetration
    • Continuous infusion 

    Target populations:

    • ICU patients
    • Patients with comorbidities
    • Patients with previous antibiotic exposure in <6 months 
    • Recent hospitalization 

    Out of scope: 

    • Patients with confirmed gram positive infections

    Ceftaroline fosamil

    Research areas to be considered for support:

    • Activity vs. resistant pathogens;
    • Prevalence of resistant gram + pathogens (e.g., penicillin NS (non-susceptible), macrolide resistant and/or ceftriaxone resistant Streptococcus pneumoniae);
    • Monitor emergence of ceftaroline resistant strains: support local in vitro surveillance to supplement data;
    • Tissue penetration;
    • Bacteremia;
    • Severe community-acquired pneumonia (CAP) (incl. MRSA- methicillin resistant staphylococcus aureus);
    • Diabetic foot infections (DFI), surgical site infections (SSI) with complications (secondary osteo), resistant pathogens, pediatrics, meningitis, endocarditis, cystic fibrosis
  • Isavuconazole

    Research areas to be considered for support:

    • Improve awareness of invasive mold infections
    • Improve clinical diagnosis, new surrogate markers and diagnostic strategies, and improve mold infections laboratory capabilities
    • Isavuconazole real-world data. Experience using isavuconazole, epidemiology of IFI and health disparity opportunities. Use in ECMO, renal and hepatic dysfunction, and switch from other azoles
    • New uses for isavuconazole. prophylaxis, combination therapy, oral switch in candidiasis, in cryptococcus meningitis, and in chronic disease
    • Disparity and equity. Vulnerable populations or/and neglected diseases as well as supporting minority mycologists in low-income countries

    Target populations:

    • Hematological malignancy
    • Intensive care units
    • Emerging patients at risk such with influenza, covid19 and new chemotherapies
    • Chronic IFI disease and chronic pulmonary disease

    Out of scope:

    • Primary treatment of candidiasis
    • Endemic mycoses: All studies in endemic mycoses (HIV and crypto after animal model, cocci animal model)


    Invasive Fungal Infections Awareness and Diagnosis

    Research areas to be considered for support:

    • Improve awareness of invasive fungal infections (yeasts and molds)
    • Improve clinical diagnosis, new surrogate markers and diagnostic strategies, and improve invasive fungal infections (yeasts and molds) laboratory capabilities
      • use of diagnostic tools, images or other techniques to enhance the knowledge in the early diagnosis of invasive fungal infections